With regard to IBS, a double blind placebo-controlled clinical report showed the lack of effect of the CRF1 selective antagonist BMS-562086 in ameliorating gastrointestinal symptoms in IBS-D patients [15]. This evidence concerns the gene CRHR1 and irritable bowel syndrome.